clinical trial · NCT07218380
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Eli Lilly and Company·phase3·recruiting·n = 450
Carcinoma, Transitional CellUrinary Bladder NeoplasmsNeoplasm MetastasisVepugratinibPlaceboEVPembrolizumab
brief summary
The purpose of this study is to test a new medicine, vepugratinib, in comparison with placebo, to see if it is safe and can help people with a bladder cancer that is advanced or has spread. Vepugratinib or placebo will be administered in combination with enfortumab vedotin and pembrolizumab. Study participation could last up to approximately 6 years.
started
Dec 12, 2025
primary completion
Oct 1, 2029
completion
May 1, 2033
last updated
Apr 17, 2026
official title
FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol